AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

NON-PREFERRED

Drug Requested: Repository Corticotropin Medications - Symptomatic Sarcoidosis

PREFERRED

provided or request may be denied.

<u> </u>				
□ Purified Cortrophin [™] Gel	☐ HP Acthar® Gel (repository corticotropin)			
(repository corticotropin)	*Member must have tried and failed preferred			
	Purified Cortrophin [™] Gel and meet all			
	applicable PA criteria below			
MEMBER & PRESCRIBER INFORMA	TION: Authorization may be delayed if incomplete.			
Member Name:				
ember AvMed #: Date of Birth:				
Prescriber Name:				
Prescriber Signature:	Date:			
Office Contact Name:				
Phone Number:	r: Fax Number:			
DEA OR NPI #:				
DRUG INFORMATION: Authorization may	y be delayed if incomplete.			
Drug Form/Strength:				
	Length of Therapy:			
Diagnosis:	ICD Code, if applicable:			
Weight:	Date:			
	ry corticotropin are related primarily to its <u>steroidogenic</u> re may be increased susceptibility to new infection and			
	ons. Adrenal insufficiency may occur after abrupt			
withurawar of the urug following prolonged t	nerapy.			

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be

M	ember <u>MUST</u> have a document	ted diagnosis of	sarcoidosis	and <u>ONE</u> of the following:		
	With active pulmonary sympton	ns OR	□ Extra	a pulmonary symptoms only		
	AND					
	 □ Member <u>must</u> have tried and failed or has a contraindication to systemic corticosteroids as follows: □ Trial of dose equivalent to at least 20 mg prednisone daily for 3 months <u>MUST</u> be noted in pharmacy claims 					
	OR					
	☐ For contraindication: GI BLEED has occurred within the last 30 days (must submit chart note documentation)cor					
	AND					
	☐ Member must have tried and failed or has a contraindication to at least <u>one</u> (1) of the following immunomodulators (therapy tried <u>must</u> be noted in pharmacy claims):					
	□ methotrexate	□ azathioprin	ie	□ leflunomide		
	AND					
	☐ Member must have tried and failed or has a contraindication to at least <u>one</u> (1) TNF Inhibitor (therapy tried <u>must</u> be noted in pharmacy claims):					
	□ infliximab (Remicade®)	etanercept (Enbrel®) 🗖 adalin		□ adalimumab (Humira®)		
	AND					
	□ Documentation that <u>EITHER</u> pulmonary imaging/pulmonary function tests <u>OR</u> noncaseating granulomas showed worsening of disease while on a steroid and immunomodulator and TNF-Inhibitor (progress notes and diagnostics <u>MUST</u> be submitted):					
	Pulmonary imaging	OR	- (Confirmation of noncaseating granulomas		
	☐ Recent pulmonary function	tests				
Medication being provided by a Specialty Pharmacy - PropriumRx						

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *